NCT05679687 is a Phase 1 clinical trial of Treatment in CAR, sponsored by The First Affiliated Hospital of Soochow University.

Who is sponsoring NCT05679687?

NCT05679687 is sponsored by The First Affiliated Hospital of Soochow University.

What drugs are being tested in NCT05679687?

Interventions in NCT05679687: Treatment.

What condition does NCT05679687 study?

NCT05679687 studies CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL.

Is NCT05679687 still recruiting?

NCT05679687 is currently status unknown. Last updated 11 January 2023.

Last reviewed 2023-01-11 · How we verify

NCT05679687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ThisCART19A Bridging to alloHSCT for R/R B-ALL

Status unknown Phase 1 Last updated 11 January 2023

What this trial tests

Phase 1 trial testing Treatment in CAR in 20 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
30 November 2025

30 November 2025

Quick facts

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2022
Primary completion	30 November 2025
Estimated completion	30 November 2025
Sites	1 location across China

Drugs / interventions tested

Treatment — full drug profile →

Conditions studied

CAR — all drugs for CAR →
Refractory Acute Lymphoblastic Leukemia — all drugs for Refractory Acute Lymphoblastic Leukemia →
Relapsed Adult ALL — all drugs for Relapsed Adult ALL →

Sponsor

The First Affiliated Hospital of Soochow University

Who can join

Adults 14 to 65, any sex, with CAR or Refractory Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) bridging to HSCT in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r B-ALL).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, et al · · 2023 · cited 108× · PMID 38187393 · DOI 10.3389/fimmu.2023.1303935
Recent updates on allogeneic CAR-T cells in hematological malignancies.
Mansoori S, Noei A, Maali A, Seyed-Motahari SS, et al · · 2024 · cited 34× · PMID 39227937 · DOI 10.1186/s12935-024-03479-y
Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma.
Zhao X, Wu J, Zhu X, Xiao Y. · · 2025 · PMID 41137502 · DOI 10.1177/09636897251379571
[Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy].
Wang ZH, Li LH, Xue SL, Zhu ZL, et al · · 2024 · PMID 39746693 · DOI 10.3760/cma.j.cn121090-20240703-00249

Verify or expand the search:

Other trials of Treatment

Trials testing the same drug.

NCT07322211 — A Study to Evaluate the Clinical Performance and Safety of UNICON Silicone Hydrogel Daily Disposable Soft Contact Lenses · NA · recruiting
NCT07339553 — Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Ep · Phase 2 · not yet recruiting
NCT07239622 — Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Ce · Phase 2 · not yet recruiting
NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting
NCT07176234 — The LEADS Trial (Linking Exericise for Advancing Daily Stress Management) · NA · recruiting

Other recruiting trials for CAR

Currently open trials in the same condition.

NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
NCT05043571 — CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia · Phase 1 · recruiting
NCT05038696 — ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. · Phase 1 · recruiting
NCT03198546 — GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression · Phase 1 · recruiting

Other The First Affiliated Hospital of Soochow University trials

Trials by the same sponsor.

NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05679687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
Last refreshed: 11 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing